Hospital Universitari Dexeus Grupo Quironsalud — Clinical Trial Site

144 Registered trials

64 Currently recruiting

Organisation

Hospital Universitari Dexeus Grupo Quironsalud

Location

Barcelona, Spain

Identifier

ORG-100030777

Address

Calle De Sabino Arana 5-19, 08028, Spain

Departments

-
1601:Oncología
Allergy
Cirugía Ortopédica y Traumatología
Consulta Oncología -1.1
Department of Gynecology and Obstetrics
Department of Reproductive Medicine
ESP007: Oncología Médica
Gynaecology
Gynecology and Obstetrics
Haematology
Hematología
Instituto Oncológico Dr Rosell
Medica Oncology
Medical Oncology
Medical Oncology Service
N/A
Neonatology department
Neurología
Obstetricia
Obstetrics and Gynecology
Onclogy
Oncología
Oncología Médica
Oncology
Oncology Department
Oncology Service
Servicio de Oncología
Servicio de Oncología - Instituto Oncológico Dr. Rosell (IOR)
Servicio de Oncologia Medica

Clinical trials at this site (144)

Search interface

Trial of Two Adagrasib Dosing Regimens in NSCLC with KRAS G12C Mutation Recruiting

2023-503523-25-00 Non-small cell lung cancer 4 2024-02-29
Evaluation of epithelial ovarian, primary peritoneal, or fallopian tube cancer treatment in first recurrance using platinum-based chemothera… Recruiting

2022-501220-14-00 epithelial ovarian, primary peritoneal, or fallopian tu 4 2023-10-17
A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Pati… Recruiting

2022-502959-54-00 Locally Advanced or Metastatic Non-Small Cell Lung Canc 5 2023-09-26
A basket study to investigate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with solid tumors Recruiting

2022-502654-14-00 Endometrial cancer 4 2023-09-11
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting

2022-501007-28-00 Breast Neoplasms 5 2023-04-18
First in human study of BAY2927088 in participants who have advanced non-small cell lung cancer (NSCLC) with mutations in the genes of epide… Recruiting

2023-503795-24-00 Avanced Non-Small Cell Lung Cancer 7 2022-09-16
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participan… Recruiting

2023-505749-14-00 c-Met overexpressing EGFR wildtype non-squamous non-sma 5 2022-03-20
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib in RET fusion-Positive NSCLC Recruiting

2023-506784-33-00 RET fusion-Positive NSCLC 5 2021-01-19
A clinical study to investigate the efficacy and safety of an investigational combination therapy with BNT324 and BNT327 in patients with ad… Recruiting

2024-520238-31-01 Advanced Lung Cancer 9 2026-04-20
A clinical trial to test if an investigational combination therapy with BNT326 and BNT327 is safe and potentially beneficial for people with… Recruiting

2024-519344-32-00 Non-small Cell Lung Cancer 9 2026-03-16
A clinical study to find the optimal dose of an investigational treatment called BNT323 when used in combination with another investigationa… Recruiting

2024-517979-20-00 Advanced Breast Cancer Metastatic Breast Cancer 9 2026-03-04
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-02) Recruiting

2025-522873-12-00 ER+, HER2- Advanced Breast Cancer 5 2026-02-24
Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Pembrolizumab with Platinum-based Chemotherapy in First-line HER2 o… Recruiting

2024-515658-26-00 Unresectable or Metastatic HER2 overexpressing and PD-L 5 2026-01-21
Effect of Semaglutide on embryo quality in overweight and obese patients undergoing In Vitro Fertilization. A Randomized Controlled Trial Recruiting

2025-522525-34-00 Infertility 6 2026-01-19
A Prospective, Open-Label, Randomized, Interventional Study to Evaluate the Efficacy and Tolerability of Sucrosomial® Iron vs Ferric Maltol … Recruiting

2025-522004-24-00 iron deficient 11 2025-12-11
An open-label randomised, phase II trial of Datopotamab deruxtecan plus Durvalumab versus Datopotamab deruxtecan in patients with PDL1-negat… Recruiting

2024-519913-76-00 PDL1-negative metastatic triple-negative breast cancer 4 2025-12-09
A phase 2 placebo-controlled trial to investigate visugromab and nivolumab with or without docetaxel in second-line treatment of participant… Recruiting

2024-516794-70-00 Metastatic non-squamous non-small cell lung cancer 4 2025-11-03
Neoadjuvant Cemiplimab Plus Imiquimod in Cutaneous Basal Cell Carcinoma. Recruiting

2025-520698-38-00 Cutaneous Basal Cell Carcinoma 9 2025-10-22
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-line Treatment of PD-L1-high Metastatic Non-small Cell Lung… Recruiting

2024-517780-24-00 Lung Cancer 5 2025-09-18
Study of Daraxonrasib (RMC-6236) in Patients with RAS Mutated NSCLC Recruiting

2024-518154-16-00 non-small cell lung cancer 5 2025-08-27
A Phase 1/2, open-label, multicenter, dose-escalation, and dose‑optimization study to evaluate the safety, tolerability, and activity of EIK… Recruiting

2024-520395-99-00 Advanced solid tumors 7 2025-08-12
Phase II, single arm, multicentre clinical trial to evaluate the activity of encorafenib plus binimetinib followed by Cemiplimab And Fianlim… Recruiting

2024-513375-40-00 Melanoma 4 2025-05-16
A study to learn more about how well treatment with sevabertinib (BAY2927088) tablets works and how safe it is in participants who have a so… Recruiting

2024-517419-62-00 HER2 mutation 4 2025-02-28
Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With Recurrent KRAS/NRAS and BRAF Wild-type Colorectal Cancer Recruiting

2024-513853-66-00 KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or 5 2025-02-04